Treatment Approaches in Advanced RCC

Dana-Farber Cancer Institute
B

Updates on the Management of Non-Clear Cell RCC

By Dana-Farber Cancer Institute FEATURING Bradley McGregor
By Dana-Farber Cancer Institute FEATURING Bradley McGregor
208 views
May 2, 2023
0 Comments
Login to view comments. Click here to Login
11:38
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Final Prespecified OS Analysis of CLEAR -…

Feat. T. Hutson
11:46
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "EV-103 Dose Escalation/Cohort A - Long-Te…

Feat. S. Gupta
07:42
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Analysis of Pt-Level Data From SWOG-1216 …

Feat. N. Sayegh
23:57
ecancer

ASCO® 2023 Summary: "Key Trials in mRCC"

Feat. J. Puente, C. Suárez, S. Oudard, V. Grünwald
19:50
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Adding Clarity to Non-Clear Cell Carcinom…

Feat. M. Schmidinger
08:22
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Efficacy and Safety Analysis of Sacituzum…

Feat. S. Tagawa
05:07
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "FGFR3 Alterations in Phase III PROOF 302 …

Feat. P. Grivas
17:19
The University of Kansas Cancer Center

The Role of Radiation Therapy in Renal Cell Carcinoma

Feat. J. Shiao
17:31
The University of Kansas Cancer Center

Updates in Renal Cell Carcinoma

Feat. S. Abbasi
13:37
SIR 2023 Conference Coverage

SIR 2023: Renal Cell Carcinoma Guidelines - What's New in 2023?

Feat. N. Kothary
14:36
OncoAlert

RCC Updates: Perioperative Treatment, Metastatic ccRCC, and Non-Clea…

Feat. T. Choueiri
10:29
UC Irvine Health

Molecular Characteristics of Advanced ccRCC Harboring TERT Mutations

Feat. N. Mar
07:39
Total Health

2023 Case-Based Clinical Updates in RCC: 69 y/o Male With Clear Cell…

Feat. D. Vaena
15:50
Pavlos Msaouel

First-Line Treatment Options in Advanced RCC: How to Choose

07:10
Viktor Grünwald

Updated Results From the CLEAR Trial: Outcomes of the Combination of…

15:17
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Systemic Therapy for Recurrent Metastatic RCC: Beyond S…

Feat. T. Zhang
56:06
Yale Cancer Center

Determinants of Effective Anti-Tumor Immunity in Kidney Cancer

Feat. D. Braun
14:14
PrecisCa

GU Tumor Board: 61 y/o Male With mRCC With Disease Progression After…

Feat. M. Rettig, S. Slovin, T. Fraum, J. Abel, P. Patel
08:16
PrecisCa

Preferred Modality for Follow-Up Imaging After Definitive Treatment …

Feat. C. Lynn Siegel
20:23
Aly-Khan A. Lalani

Choosing Wisely: 1L Combination Treatment for Advanced RCC

10:55
Yale Cancer Center

Systemic Therapies for Clear Cell RCC: Where Are We Now?

Feat. D. Braun